Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|Akari Therapeutics Reports First Quarter...||05/29/19|
|Positive initial clinical data reported in ongoing bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) clinical trialsFurther clinical data ...|
|Date||04/12/2019 (AMC)||Est. (EPS/Rev.)||$1.37|
|Actual (EPS/Rev.)||$2.5B||EPS (TTM)||$???|